Addis Ababa, April 30, 2020 (FBC) – German pharmaceutical company BioNTech has begun testing a potential vaccine for the new coronavirus on volunteers.
BioNTech, which is working with the US-based Pfizer, said on Wednesday that 12 participants of a clinical trial in Germany received doses of the vaccine candidate BNT162 since April 23.
Numerous pharmaceutical companies are racing to deliver a vaccine for the virus that has caused a pandemic and led to more than 215,000 deaths worldwide and sickened at least three million people.
BioNTech said in a statement that in the next step, it will begin increasing the dose of BNT162 in a trial involving about 200 participants aged 18 to 55.
The company said it expects to receive regulatory approval to begin trials in the United States soon.
As many as 100 potential COVID-19 candidate vaccines are now under development by biotech and research teams around the world, and at least five of these are in preliminary testing in people in what are known as Phase 1 clinical trials.